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Adipose tissueThe major risk factors for non-alcoholic fatty liver disease (NAFLD) are obesity, insulin resistance and
dyslipidemia. The cause for progression from the steatosis stage to the inﬂammatory condition (non-alcoholic
steatohepatitis (NASH)) remains elusive at present. Aim of this study was to test whether the different stages
of NAFLD as well as the associated metabolic abnormalities can be recreated in time in an overfed mouse
model and study the mechanisms underlying the transition from steatosis to NASH.
Male C57Bl/6J mice were subjected to continuous intragastric overfeeding with a high-fat liquid diet (HFLD)
for different time periods. Mice fed a solid high-fat diet (HFD) ad libitum served as controls. Liver histology and
metabolic characteristics of liver, white adipose tisue (WAT) and plasma were studied.
Both HFD-fed and HFLD-overfed mice initially developed liver steatosis, but only the latter progressed in time
to NASH. NASH coincided with obesity, hyperinsulinemia, loss of liver glycogen and hepatic endoplasmatic
reticulum stress. Peroxisome proliferator-activated receptor γ (Pparγ), ﬁbroblast growth factor 21 (Fgf21),
fatty acid binding protein (Fabp) and fatty acid translocase (CD36) were induced exclusively in the livers of
the HFLD-overfed mice. Inﬂammation, reduced adiponectin expression and altered expression of genes that
inﬂuence adipogenic capacity were only observed in WAT of HFLD-overfed mice.
In conclusion: this dietary mousemodel displays the different stages and themetabolic settings often found in
human NAFLD. Lipotoxicity due to compromised adipose tissue function is likely associated with the
progression to NASH, but whether this is cause or consequence remains to be established.31 20 5669190.
s).
ands.
l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
If hepatic import and synthesis of triglycerides exceeds hepatic
triglyceride export and oxidation, triglycerides accumulate in the
hepatocytes (steatosis stage of non-alcoholic fatty liver disease
(NAFLD)). Several genetic and dietary animal models have been
used to study the progression from steatosis to the stage of
steatohepatitis or inﬂamed fatty liver (NASH; reviewed a.o. by Larter
and Yeh [1]). However, the mechanisms underlying this transition
have remained largely obscure due to a lack of animal models that
simulate the etiology of the human disease. The severity of steatosis is
signiﬁcantly associated with NASH [2,3] and only part of the patients
progress to steatohepatitis. Therefore it has been hypothesized that a
‘double hit’ is required for the development of NASH [4]: the ﬁrst
producing steatosis and sensitizing the liver for the second hit i.e.,oxidative stress [5] or (endotoxic) cytokines [6]. However, an
obligatory role for oxidative stress in the progression to NASH could
not been shown [7], which led to the alternative “lipotoxicity”
hypothesis (reviewed by Neuschwander-Tetri [8]). Lipotoxicity
attributes cellular injury and death to fatty acids and/or their
metabolites [9,10]. Although intracellular fatty acid concentration is
quite constant in hepatocytes [11], the ﬂux of fatty acids through the
liver is increased in NASH patients [12,13]. This may be caused either
through increased supply by excessive or inappropriate adipocyte
lypolysis [14] or excessive de novo lipogenesis [15]. Combinedwith an
imbalanced fatty acid oxidation, lipotoxicity may occur.
NAFLD is a highly prevalent disease, the worldwide incidence of
which has increased signiﬁcantly concomitant with the increase in the
number of obese people [16]. The most common cause of obesity in
man is a chronic intake of a hypercaloric diet rich in (saturated) fats.
Deng et al. [17] developed a NAFLD model in which mice were
continuously overfed a high-fat diet via a gastrostomy tube for
9 weeks. Thesemice became obese, insulin-resistant and diabetic, and
developed steatohepatitis. In the present study, we used a similar
mouse model in a longitudinal study to follow the development of
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underlying the progression from steatosis to NASH.
2. Materials and methods
2.1. Surgical procedure and dietary regimen
Ten-weeks old, male C57Bl/6J mice (Harlan NL) had a catheter
inserted into the forestomach via a purse string suture. The catheter
was attached to a 20G swivel to allow continuous infusion of feed and
free movement of the mice (all infusionmaterials: Instech USA). From
5 post-operative days onwards, the mice were fed a, high-fat liquid
diet (L10049, Research Diets, USA; Supplementary Table 1) for 3, 6 or
12 weeks (HFLD-overfed, n=3/group). The daily amount of feed
administrated increased in time from 580 kCal/kg BW (t=0) to
750 kCal/kg BW (t=3d), 870 kCal/kg BW (t=7d), to the maximally
tolerated amount of 920 kCal/kg BW (t=19d; 27 kCal/day). After this,
kCal/kg BW declined in time due to the maximized intake and
increasing bodyweight (see Supplementary Fig. 1). A control group of
10-weeks old male C57Bl/6J mice (Harlan) without catheter had ad
libitum access to a solid high-fat diet (D06092602, Research Diets;
Supplementary Table 1) for 3, 6 or 12 weeks (HFD-fed, n=3, 5 and 5
per group resp.). As a reference for normal values, a third group
(n=6) of male C57Bl/6J mice (Harlan NL) was included that received
standard chow (Special Diets Services, #801730) andwas sacriﬁced at
the age of 17 weeks (comparable to 6 weeks fed HFD and HFLD). All
mice had ad libitum access to water throughout the experiment. Mice
were sacriﬁced around noon by decapitation after a brief sedation
with CO2/O2 (70:30). Systemic blood was immediately collected into
heparin-coated Pst LH microtainer tubes (BD, USA) and centrifuged.
The resulting plasma was frozen in liquid N2 and stored at −80 °C.
Epididymal fat pads were removed, weighed, frozen in liquid N2 and
stored at −80 °C. The liver was removed, weighed, and parts were
either ﬁxed in 4% formaldehyde/PBS or frozen in liquid N2 and stored
at −80 °C. All experimental procedures were approved by the
Institutional Animal Care and Use Committee of the AcademicMedical
Center.
2.2. MRI analysis of whole-body adipose tissue
After 6 weeks of diet, whole body adipose volumes were assessed
(n=3mice/group) under ketamine-medetomidine anesthesia using a
clinical 3.0 T Philips Intera MRI scanner (Philips Healthcare, Best, The
Netherlands). Coronal whole body images of mice in prone position
were acquiredwith a receive-only surface coil (5 cmdiameter) using a
T1-weighted Turbo Spin Echo sequence (parameters: TE/TR=15/
183 ms, NSA=3, slice thickness 1.3 mm, no slice gap, in plain
resolution 1.5×1.5 mm,ﬁeld of view 90×60 mm). The signal intensity
was highest at the level of the used MRI coil and lower at the cranial
and caudal ends of the mice. Therefore, the signal intensity of adipose
tissue along the body axis was measured in each transversal section, a
conversion factorwas calculated and used to normalize each section to
the mid-coil section. This intensity correction was implemented in
MATLAB (The MathWorks, Natick, MA, USA) and enabled computer-
ized separation of adipose tissue from other tissues in 3D. The
processed image data sets were segmented and intra-abdominal (i.e.,
within the peritoneal cavity) and whole-body fat volumes were
determined using Amira software (Template Graphic Software,
Mercury Computer Systems). To segment images, a manual threshold
was set to separate the high intensity signal of adipose tissue from the
lower intensity signal of non-fatty tissues and background. A lower
threshold was used to separate the complete animal from the
background. This way the volumes of adipose tissue and of the
complete animal were determined. This was followed by manual
separation of visceral and non-visceral fat in the images to determine
relative visceral fat volume.2.3. Plasma analyses
Plasma levels of alanine aminotransferase (ALAT), aspartate
aminotransferase (ASAT), gamma-glutamyl transpeptidase (γ-GT),
alkaline phosphatase (AP) and bilirubin were determined in a Hitachi
911 analyzer (Roche/Hitachi, Indianapolis, IN). Plasma insulin was
measured with the “Ultra Sensitive Mouse Insulin ELISA” kit (Chrystal
Chem Inc, USA). Plasma TNFα was measured with the “Mouse TNFα
ELISA MAX” kit (BioLegend, USA). Plasma IL-6 was measured with the
“BD OptEIAMouse IL-6 ELISA” kit (BD Biosciences, USA). For detection
of FABP4 protein in plasma of 6 weeks HFD-fed and HFLD-overfed
mice (all n=3/group), equal amounts of plasma were loaded on a
polyacrylamidegel. Proteins were blotted on PVDF membrane and
detected with a rabbit polyclonal FABP4 antibody (Cell Signaling,
USA) and appropriate HRP-labeled 2nd antibody (DAKO). Chemilu-
minescent signals were detected using “Lumilight Plus” (Roche).
2.4. Oral glucose-tolerance test
Mice were fasted for 5 h after which blood glucose (t=0) was
measured in a drop of tail vein blood using an Elite Glucometer
(Roche). In addition, a few drops of blood were collected in a heparin-
coated PST LHMicrotainer (BD, USA) to enablemeasurement of fasted
insulin levels. Thenmice orally received D-glucose (20% w/w solution;
1 g/kg BW). After 10, 20, 30, 60 and 90 min, blood glucose was
measured in a drop of tail vein blood. The area under the curve was
calculated by the trapezoidal method.
2.5. Biochemical liver analyses
Lipids were extracted from 50 to 100 mg of liver as described [18].
Triglycerides were measured using the “Trig/GB” kit (Roche). NEFA
were measured using the “NEFA c” kit (WAKO, Germany). Cholesterol
was measured using the “Cholesterol RTU” kit (Biomerieux, France).
Phospholipids were measured using the “Phospholipids” kit (Spinreact,
Spain).
2.6. Western blot analyses
50 to 100 mg of liver was homogenized in RIPA buffer (20 mM Tris
(pH7.5), 150 mM NaCl, 1% NP40, 5 mM EDTA, 0.5 mM DTT, 0.2 mM
PMSF)with protease and phosphatase inhibitors (both Roche). Proteins
(equal μg/lane) were separated by 10% SDS-PAAGE and transferred to
PVDFmembrane (Millipore).Membraneswere blocked in5%BSA/TBS-T
(50 mMTris, 150 mMNaCl, 0.1%Tween-20 (pH7.5)), incubatedwith1st
antibody (P-Ser473-Akt, panAkt, P-Ser51-eIF2α or eIF2α (all Cell
Signaling, USA)) and appropriate HRP-labeled 2nd antibody (all
DAKO). Chemiluminescent signals were detected and quantiﬁed using
“Lumilight Plus” (Roche) and a Lumi-Imager F1 (Roche).
2.7. (Immuno)histochemistry
Liver histology was assessed by staining formaldehyde-ﬁxed liver
sections with PicroSiriusRed (for ﬁbrosis) and Periodic Acid Schiff (for
glycogen) or by staining cryosections with Oil Red O (for steatosis).
Macrophages (both inﬁltrating and liver-resident (Kupffer cells))
were detected in cryosections with an α-F4/80 antibody (AbD
Serotec) and activated macrophages with an α-CD11b (Mac1)
antibody (R&D systems). Inﬁltrating granulocytes and monocytes
were stained with a Ly6/Gr1 antibody (BD Pharmingen).
2.8. Hepatic gene expression analyses
RNA was isolated from 50 to 100 mg frozen liver using Trizol
reagent (Invitrogen, NL). cDNAwas synthesized using locked oligo-dT
primers (5′-TTT TTT TTT TTT TTVN-3′) and Superscript III reverse
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Lightcycler 2.0 with the “FastStart DNA MasterPlus SYBR Green I” kit
(Roche). Primers are shown in Supplementary Table 2. Raw Light-
cycler data were analyzed using the LinReg program [19]. Measure-
ments were corrected for between-session variation [20] and
normalized for their 18S content.Fig. 1. Changes in bodyweight (A), liver weight (B) and fat-pad weight (C) in C57Bl6/J mice ad
12 weeks (HFD: n=3, 5 and 5 per group, resp. HFLD: n=3 per group, resp.). Chow-fed mic
body fat in C57Bl6/J mice ad libitum fed a solid high-fat diet (HFD) or overfed a high-fat liqu
MRI. (F) Ratio of intra-abdominal fat volume to total body fat volume as determined by M
different from other groups within diet (pb0.05); γ: signiﬁcantly different from chow (pb2.9. Statistical analyses
Data are expressed as mean values±SEM. All statistical tests were
performed with SPSS 14.0. Data were ﬁrst analyzed by two-way
ANOVA to assess differences between the diet groups as a whole.
Subsequently one-way ANOVA per time point and per diet waslibitum fed a solid high-fat diet (HFD) or overfed a high-fat liquid diet (HFLD) for 3, 6 or
e (n=6) were included as reference for normal values. (D) MRI quantiﬁcation of total
id diet (HFLD) for 6 weeks (n=3/group). (E) Volume% total body fat as determined by
RI. Values represent means±SEM. *: signiﬁcantly different (Pb0.05); #: signiﬁcantly
0.05).
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isons. P≤0.05 was considered statistically signiﬁcant.
3. Results
3.1. Overfeeding a high-fat liquid diet results in a progressive increase in
body, liver and fat-pad weights
Feeding C57Bl/6J male mice ad libitum a solid, olive-oil based,
high-fat diet (HFD) resulted in a continuous and modest bodyweight
gain of 20% in a period of 12 weeks (Fig. 1A). This is comparable to the
normal weight gain of chow-fed C57Bl/6J male mice of similar age. In
contrast, overfeeding a high-fat liquid diet (HFLD) for the same period
resulted in a ~2.5-fold increase in bodyweight (Fig. 1A). The liver
weights, both absolute and relative to bodyweight, were signiﬁcantly
increased in the HFLD-overfed mice only (Fig. 1B and Supplementary
Fig. 2). The biggest effect was seen on the weight of the epididymal fat
pads, especially after 6 and 12 weeks of HFLD feeding (Fig. 1C and
Supplementary Fig. 2). Remarkably, the relative weights of the liver
and fat pad returned to control values after 6–12 weeks of the HFD
diet, whereas the effects persisted in HFLD-fedmice. Body fat volumes
were also quantiﬁed using MRI imaging (Fig. 1D). The body volume
and total body fat volume of the mice correlated tightly with
bodyweight and epidydimal fat pad weight, respectively (see
Supplementary Fig. 2). The percentage total body fat almost doubled
in 6 weeks HFLD-overfed mice compared to 6 weeks HFD-fed mice
(Fig. 1E). Interestingly, the contribution of intra-abdominal fat to total
body fat content was not different between HFD-fed and HFLD-
overfed mice (Fig. 1F).
3.2. In overfed mice liver steatosis is more persistent than in HFD-fed
mice
A prominent accumulation of lipid droplets was seen in the liver
from the earliest time point (3 weeks) onwards in both HFD-fed and
HFLD-overfed mice, but the zonal distribution of the lipid droplets
was remarkably different between both high-fat fed groups (Fig. 2A
and Supplementary Fig. 3). Lipid accumulated predominantly in
relatively large vesicles situated around the portal veins in the HFD-
fed groups. In the HFLD-overfed mice, initially a homogeneous
accumulation of small lipid vesicles was observed. However, after
12 weeks of overfeeding, also large lipid droplets were present around
the portal veins in addition to the homogeneously distributed smaller
lipid vesicles (Fig. 2A and Supplementary Fig. 3).
Liver triglyceride levels were N10-fold higher in HFD-fed and
HFLD-overfed mice than in chow-fed mice (Fig. 2B). Between 3 and
12 weeks on the high-fat diet, hepatic triglyceride content in the HFD-
fed mice decreased, whereas it remained elevated in the HFLD-
overfed mice (see Fig. 2B). Hepatic cholesterol, free fatty acids and
phospholipids were also signiﬁcantly increased in both HFD-fed and
HFLD-overfed mice compared to chow-fed mice (data not shown)
The persistent steatosis in the HFLD-overfed mice was also reﬂected
by the signiﬁcantly increased hepatic mRNA expression of two
markers of steatotic livers: peroxisome proliferator-activated receptor
γ [21,22] (Pparγ, Fig. 2C) and ﬁbroblast growth factor 21 [23,24]
(Fgf21; Fig. 2C).
Remarkably, plasma TG levels decreased ~5-fold with time in mice
on the HFD diet (Fig. 2D). In mice on the HFLD diet, plasma TG levels
were similar to those in chow-fed mice for the ﬁrst 6 weeks on the
diet, but decreased ~2-fold between 6 and 12 weeks on the diet.
Plasma cholesterol levels were ~50% increased in both HFD-fed andFig. 2. (A) Representative Oil Red O staining of liver sections of C57Bl6/J mice chow-fed (chow
or overfed a high-fat liquid diet (HFLD: n=3/group, resp.) for 3, 6 or 12 weeks (magniﬁcat
Fgf21 relative to 18S RNA in the livers of these mice. (D) Plasma triglycerides and cholest
#: signiﬁcantly different from other groups within diet (pb0.05); γ: signiﬁcantly differentHFLD-overfed mice from the earliest time point on the high-fat diet
onwards (Fig. 2D). Plasma NEFA levels were not signiﬁcantly different
at any time point between any of the diets (not shown). Plasma ALAT,
ASAT, AP, γ-GT or bilirubin levels were not signiﬁcantly elevated in
the experimental groups (data not shown).
3.3. Overfeeding causes hyperinsulinemia, but no insulin resistance
Plasma glucose levels did not differ signiﬁcantly between chow-
fed, HFD-fed and HFLD-overfed mice in either the fasted or the non-
fasted condition (not shown). In contrast, fasted insulin levels and
insulin resistance, as deﬁned by an Oral Glucose Tolerance Test
(OGTT), were slightly but signiﬁcantly increased in the ad libitum fed
group compared to the chow- and overfed groups at 6 weeks of
feeding (Fig. 3A and Supplementary Fig. 4A, respectively). However,
non-fasted insulin levels were signiﬁcantly higher in the 12 weeks
overfed mice (Fig. 4B). In the livers of 6 and 12 weeks HFLD-overfed
mice, normal insulin signaling was still apparent: the degree of
phosphorylation of Akt/PKB was increased (Fig. 4C) and correlated
positively with plasma insulin levels (R2=0.99; Supplementary
Fig. 4B). Phosphorylation of glycogen synthase kinase 3β (GSK3β), a
target of Akt/PKB, was also observed in the livers of 6 and 12 weeks
HFLD-overfed mice; this correlated with the phosphorylation of Akt/
PKB (data not shown).
3.4. Increased lipogenesis and lipid uptake in livers of overfed mice
To uncover putative mechanisms involved in the observed
steatosis, the expression of a number of key mediators of carbohy-
drate and lipidmetabolismwas studied. ThemRNA expression of fatty
acid synthase (Fas) and stearylCoA desaturase 1 (Scd1), both key
factors in lipogenesis, were unchanged in HFD-fed mice but were
increased in the HFLD-overfed mice (Fig. 4A). In addition, the mRNA
levels of fatty acid translocase (Fat/CD36) and fatty acid binding
protein (Fabp), involved in fatty acid uptake and intracellular fatty
acid binding respectively, were also exclusively increased in the livers
of HFLD-overfed mice (Fig. 4B). Moreover, plasma FABP4 protein
levels differed substantially between HFD-fed and HFLD-overfed mice
(Fig. 4C).The mRNA levels of carnitine palmitoyltransferase 1 (Cpt1a),
acetylCoA oxidase 1 (Acox1) and peroxisome proliferator-activated
receptor α (Pparα), all involved in fatty acid oxidation, were not
different in time and between diets (data not shown). Similarly, the
mRNA expression levels of phosphoenolpyruvate caboxykinase (Pck),
glucokinase (Gck) and carbohydrate-responsive element-binding
protein (Chrebp [25]), all involved in carbohydrate metabolism,
were unchanged in all groups (data not shown).
3.5. Inﬂammation becomes apparent with time in HFLD-overfed mouse
livers only
Hepatic inﬂammation was assessed by immunohistochemical
staining of liver sections and measuring hepatic mRNA expression
of inﬂammationmarkers. Staining for the general macrophagemarker
F4/80 showed that the number of macrophages did not differ
appreciably between chow-fed, HFD-fed and HFLD-overfed mice
(Fig. 5A). At the mRNA level, liver F4/80 expression increased ~2-fold
in HFLD-overfed mice compared to chow- and HFD-fedmice (Fig. 5B).
However, the number of CD11b/Mac1-positive (activated) macro-
phages was signiﬁcantly higher in the HFLD-overfed mice at all times
and increased with time to a ~10-fold difference at 12 weeks (Fig. 5A
and B). The mRNA expression of Toll-like receptor 4 (Tlr4), also, n=6/group), ad libitum fed a solid high-fat diet (HFD: n=3, 5 and 5 per group, resp.)
ion: 5×). (B) Liver triglycerides (TG) of these mice. (C) mRNA expression of Pparγ and
erol of these mice. Values represent means±SEM. *: signiﬁcantly different (pb0.05);
from chow (pb0.05); $: signiﬁcantly different from all other groups (pb0.05).
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Fig. 3. (A) Plasma insulin levels of C57Bl6/J mice ad libitum fed a solid high-fat diet
(HFD: n=3, 5 and 5 per group, resp.) or overfed a high-fat liquid diet (HFLD: n=3/
group, resp.) for 3, 6 or 12 weeks. Values represent means±SEM. $: signiﬁcantly
different from all other groups (pb0.05). (B) Amount of phospho-Akt/PKB (P-AKT) and
total Akt on a Western blot of total protein isolated from livers of C57Bl6/J mice ad
libitum fed a solid high-fat diet (HFD: n=5/group, resp.) or overfed a high-fat liquid
diet (HFLD: n=3/group, resp.) for 6 or 12 weeks. Two representative samples of each
group were loaded on the gel. Equal amounts of protein were loaded in each lane.
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shown). Most remarkable was the induction of mRNA expression of
myeloperoxidase (Mpo) from virtually absent in chow-fed and HFD-
fed mice to ~1500-fold higher levels in 12-weeks HFLD-overfed mice
(Fig. 5B). Mpo is expressed in neutrophils and monocytes, but also in
Kupffer cells [26]. The more pronounced increase in Mpo than in
Mac1/CD11b expression implies that the increase inMpo expression in
the livers of HFLD-overfed mice largely reﬂects inﬁltrating neutro-
phils. Indeed, numerous clusters of inﬂammatory cells containing Ly6/
Gr1-positive neutrophils or monocytes were found in the livers of
HFLD-overfed mice (Fig. 5C).
None of the livers showed signs of extensive liver ﬁbrosis except
that of one 12-weeks HFLD-overfed mouse that showed extensiveﬁbrosis (Supplementary Fig. 5). This ﬁbrosis co-localized with large
inﬂammatory foci. In agreement, the hepatic mRNA expression of
α1procollagen (I) was not different between the different experi-
mental groups (data not shown).
Hepatic oxidative stress and lipid peroxidation are implicated in
the progression of fatty livers to NASH [27–29]. However, the fraction
of oxidized glutathione (GSH/GSSG) did not differ between the
experimental groups (Supplementary Fig. 6A). Furthermore, the
expression of oxidative stress markers Nrf2, catalase and Cyp2E1
was not different between HFD-fed and HFLD-overfed mice (Supple-
mentary Fig. 6B). The expression of heme oxygenase 1 (Ho-1), which
may respond to oxidative stress [27,30], was ~3-fold induced in the
livers of HFLD-overfed mice (Fig. 6A).
Fatty-acid accumulation and exposure to cytokines both induce
endoplasmatic reticulum (ER) stress, which, in turn, causes increased
expression of the transcription factor C/EBP-homologous protein
(Chop) [31]. Signiﬁcantly increased levels of Chop mRNA were found
exclusively in the livers of 12 weeks HFLD-overfed mice (Fig. 6B). In
accordance, increased phosphorylation of elongation initiation factor
2α (eIF2α), the ﬁrst signaling intermediate of the stress kinases [31],
was found in this group only (Fig. 6C). In contrast, no differences in
the splicing of Xbp1 mRNA were observed between the respective
groups, which excludes a role for the stress kinase Ire1α in the
observed ER stress (data not shown).
With the exception of one (12-weeks HFD-fed) mouse, all chow
and HFD-fed mice displayed a normal glycogen content (Fig. 7). In
contrast, all 12-weeks HFLD-overfedmice had virtually no glycogen in
their hepatocytes. The HFLD mice gradually lost their liver glycogen,
because only ~one-third of the 6-weeks HFLD group had decreased
amounts of glycogen in their hepatocytes. The loss of glycogen
correlated with the increased expression of inﬂammation markers.
3.6. Overfeeding leads to inﬂamed adipose tissue with compromised
metabolic function
Plasma tumor necrosis factor α (TNFα) levels were signiﬁcantly
increased at all time points in the HFLD-overfed mice only (Fig. 8A).
Plasma interleukin-6 (IL6) levels also tended to be increased, though
this was not statistically signiﬁcant (Supplementary Fig. 7). mRNA
analyses showed an approximately 20 times higher expression of both
Tnfα and Il6 in adipose tissue compared to liver (Fig. 8B; only WAT
shown); hence the majority of the increased plasma IL-6 and TNFα
levels in the overfed mice originates from adipose tissue. In addition,
the mRNA expression of the general macrophage marker F4/80 and
activated macrophage marker CD11b/Mac1 was also signiﬁcantly
increased in WAT of HFLD-overfed mice (Fig. 8C). In contrast, the
mRNA expression of adiponectin, an anti-inﬂammatory adipokine,
was signiﬁcantly reduced in WAT of HFLD-overfed mice (Fig. 8D).
Furthermore, the expression of vascular endothelial growth factor α
(Vegfα; Fig. 8E), involved in vascularization and often linked to
adipogenesis [32], and the expression of adipocyte differentiation
markers Pparγ and c/Ebpα, were signiﬁcantly decreased in WAT of
HFLD-overfed compared to HFD-fed mice (Fig. 8F; only c/Ebpα
shown). Similar results were observed for the expression of the
fatty-acid transporter CD36 and the lipid chaperone Fabp4 (aP2)
(Fig. 8F; only aP2 shown).
4. Discussion
Preferably, an animal model of NAFLD should display the same
liver pathology as seen in human NAFLD, i.e., steatosis, steatohepatitis
and steatohepatitis plus ﬁbrosis. In addition, this pathology should
occur within the metabolic setting that is often present in human
NAFLD: obesity, insulin resistance, dyslipidemia, and altered serum
adipokine levels. This study used intragastric overfeeding of micewith
a high-fat liquid diet [17] to induce obesity and tested whether NAFLD
Fig. 4.mRNA expression of Fas and Scd1 (A) and of Fabp and Fat/Cd36 (B), relative to 18S RNA in the livers of chow-fed (n=6), HFD-fed (n=3, 5 and 5 per group, resp.) and HFLD-
overfed mice (n=3/group, resp.). Values represent means±SEM. *: signiﬁcantly different (pb0.05). C. Detection of FABP4 protein in plasma of 6 weeks HFD-fed and HFLD-overfed
mice (all n=3/group). Equal amounts of plasma were loaded in each lane.
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in time. This proved to be so and as such, our data are a longitudinal
extension of the data from Deng et al. [17] with a comparable but
slightly less severe phenotype at the late stage of overfeeding.
Although the mice in both studies are equally obese, a remarkable
difference between this study and that of Deng et al. [17] is the
respective absence and presence of insulin resistance. The latter may
be explained by the use of different diet compositions in both studies.
The lipid composition is comparable between the diets in both
studies, both in terms of caloric value as well as percentage of
saturated lipids. However, whereas the Deng diet uses solely (high
glycemic index) glucose as carbohydrate source, (low glycemic index)
maltodextrin is the main carbohydrate source in the present study. A
low glycemic index diet has been shown to reduce diabetes incidence
and improve diabetes control [33]. The sometimes relatively high
variation in the markers we studied can be readily explained by the
experience from human studies that only a fraction of patients with
steatosis progress to steatohepatitis and ﬁbrosis, and that not all
patients do so at the same moment. Our rare observation of extensiveﬁbrosis in mice corresponds with this relatively infrequent sequel of
steatosis.
The livers of the overfed mice were metabolically characterized by
an increased expression of (pericentrally located) lipogenic genes
(Fas, Scd1 and Pparγ), combined with a high portal inﬂow of dietary
FFAs. These nutritional and metabolic sources of fat explain the
observed initial homogeneous lipid accumulation in the livers of these
mice. At later stages, the basal expression of lipolytic genes (Cpt1a,
Acox1 and Pparα), combined with the maximal inﬂow of dietary FFAs,
cause the observed periportal lipid accumulation on top of the initially
homogeneous steatosis. Unfortunately, the zonation of hepatic lipid
accumulation has not been determined in other diet-induced obesity
studies [17,34–37]. Carbohydrate metabolism seems to play at best a
minor role in our overfed mouse model, since the expression of key
factors in gluconeogenesis and glycolysis is not altered.
The mRNA expression of peroxisome proliferator-activated recep-
tor γ (Pparγ) and ﬁbroblast growth factor 21 (Fgf21) is signiﬁcantly
induced only in the livers of the HFLD-overfed mice. Previous studies
have shown overexpression of both Pparγ and Fgf21 in the steatotic
Fig. 5. (A) Liver sections of C57Bl6/J mice chow-fed (n=6), ad libitum fed a solid high-fat diet (HFD: n=5/group) or overfed a high-fat liquid diet (HFLD: n=3/group) for 6 or
12 weeks stained for the general macrophage marker F4/80 (top row) or for Mac1/CD11b (activated macrophages). Magniﬁcation: 10×. (B) mRNA expression of F4/80,Mac1/CD11b
andmyeloperoxidase (Mpo) relative to 18S RNA in the livers of these mice. Values represent means±SEM *: signiﬁcantly different (pb0.05). (C) Liver sections of these mice stained
for Ly6/Gr1 (granulocytes, monocytes). Magniﬁcation: 20×.
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patients [23,24,40]. In addition, it has been shown that PPARγ may
induce FGF21 expression in mature murine 3T3L1 adipocytes [41].
Both PPARγ and FGF21 have profound effects on (lipid) metabolism,
but a causal relationship between PPARγ and FGF21 in liver steatosis
or steatohepatitis has not yet been established. Our data suggest such
a relationship, but this requires further investigation. PPARα has also
been reported to induce liver Fgf21, but since we ﬁnd no increased
expression of Pparα in liver of HFLD-overfed mice, PPARα is a less
likely candidate for Fgf21 induction
Hepatic steatosis per se is insufﬁcient to initiate steatohepatitis, as
mice ad libitum fed a solid high-fat diet did develop steatosis to a
similar extent as mice overfed a near-identical high-fat liquid diet, but
showed no increased prevalence of NASH (see also [1,36,42]).
According to the “two hit” hypothesis [4,43], oxidative stress andpro-inﬂammatory cytokine-mediated hepatocyte injury are two
putative mechanisms thought to be involved in progression to
NASH. In our overfed mouse model we ﬁnd no increased expression
of oxidative stress markers, but we do observe increased cytokine
levels.
We hypothesize that the origin for progression to NASH may very
well lie within the inability of the overfed mice to adapt to the caloric
overload, which leads to the severely increased adipose mass that is
present in these mice. Whereas the ad libitum fed mice decrease their
caloric intake which even results in a reduced adipose mass after 6
and 12 weeks of HFD feeding, the adipose mass in the overfed mice
more than doubles from 3 to 12 weeks of overfeeding. Several studies
show a relationship between adipose tisue expandibility and
susceptibility to the metabolic syndrome [44–47]. Two non-exclusive
models have been proposed to account for this phenomenon: In the
Fig. 6.mRNA expression of Ho-1 (A) and Chop (B), relative to 18S RNA in the livers of chow-fed (n=6), HFD-fed (n=3, 5 and 5 per group, resp.) and HFLD-overfed (n=3/group,
resp.) mice. Values represent means±SEM. *: signiﬁcantly different (pb0.05); γ: signiﬁcantly different from chow (pb0.05); (C) Amount of phospho-eIF2α (P-eIF2α; lower panel)
and total eIF2α (top panel) on aWestern blot of total protein isolated from livers of C57Bl6/J mice chow-fed (C), ad libitum fed a solid high-fat diet (HFD) or overfed a high-fat liquid
diet (HFLD) for 6 or 12 weeks (n=3–5 per group). Two representative samples of each group were loaded on the gel. Equal amounts of protein were loaded in each lane.
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tion, increased cytokine production and altered adipokine secretion of
WAT. Both cytokines and adipokines inﬂuence metabolism in
peripheral tissues. In the second, lipotoxicity, model, adipocytes are
metabolically changed which results in a decreased lipid storage
capacity and increased lipid outﬂow. This causes lipotoxicity in
peripheral organs. Our overfed mouse model likely displays both
mechanisms since increased expression of inﬂammation markers and
decreased expression of adiponectin, adipocyte differentiation mar-
kers Pparγ and c/Ebpα and the lipogenic genes Fat/CD36 and Fabp4/
aP2 are observed in WAT of HFLD-overfed mice compared to WAT of
HFD-fed mice. In addition, increased plasma FABP4 and increased
hepatic expression of Fat/CD36 and Fabp are observed in HFLD-
overfed mice compared to HFD-fed mice. These observations suggest
an increased ﬂux of fatty acids through the overfed mouse livers,
similar to that observed in NAFLD patients [12,13], making the
lipotoxity hypothesis a likely explanation for the observed steatohe-
patitis in our overfed mice.Fig. 7. Liver sections of C57Bl6/J mice chow-fed (n=6), ad libitum fed a solid high-fat diet (H
or 12 weeks stained for glycogen content by Periodic acid Schiff staining. Magniﬁcation: 5×Increased visceral fat mass along with a changed serum adipokine
and cytokine proﬁle is prevalent in human NAFLD (Fan and Farrell
[48] and references therein). Blood coming from visceral fat drains
directly into the liver. It is therefore tempting to speculate that the
increased inﬂow of pro-inﬂammatory cytokines and fatty acids and
decreased inﬂow of anti-inﬂammatory adiponectin leads to the
observed increase of liver macrophages and other inﬁltrating
inﬂammatory cells. The above mechanisms may also account for
other observed phenomena in our overfed mouse model: increased
phosphorylation of eIF2α and mRNA expression of Chop, both
markers of endoplasmatic reticulum (ER) stress, and decreased liver
glycogen storage. Previous studies have shown that fatty acids and
cytokines are associated with ER stress, both in rodents [49,50] and in
NAFLD patients [51]. In addition, fatty acids may decrease glucose
conversion into glycogen [52,53].
In conclusion, the overfed mouse model displays the character-
istics of human NAFLD within the appropriate metabolic setting, i.e.,
obesity through overcaloric intake of a high-fat diet. It is shown thatFD: n=5/group, resp.) or overfed a high-fat liquid diet (HFLD: n=3/group, resp.) for 6
. A representative section for each group is shown.
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457I.C. Gaemers et al. / Biochimica et Biophysica Acta 1812 (2011) 447–458the transition from steatosis to NASH coincides with major changes in
adipose tissue. The causal relationship between NASH and the
compromised function of inﬂamed adipose tissue requires further
study.
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